Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01737398
Recruitment Status : Completed
First Posted : November 29, 2012
Last Update Posted : June 19, 2018
Information provided by (Responsible Party):
Ionis Pharmaceuticals, Inc.

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : March 3, 2017
  Actual Study Completion Date : November 7, 2017
  Certification/Extension First Submitted : April 25, 2018

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 November 2, 2018
Publications automatically indexed to this study by Identifier (NCT Number):